Please assess the completion status of the following clinical trial:

Trial Title: Antihypertensive Efficacy and Tolerability and Determine the Adequate Antihypertensive Dosage of Fimasartan in Mild to Moderate Essential Hypertension Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Mild to moderate essential hypertension : sitting diastolic blood pressure measured at Screening and Baseline(Day1) are 95\~114 mmHg inclusive and the difference between sitting diastolic blood pressures measured at Day -14 and Baseline(Day1) is under 7mmHg.~* Subjects who agree to participate in this sudy and give written informed consent~* Subjects considered to understand the study, be cooperative, and able to be followed-up until the end of the study~Exclusion Criteria:~* The sitting DBP is less than 94mmHg or more than 115mmHg or severe hypertensive patient with sitting systolic blood pressure over 200mmHg~* Patients with secondary hypertension~* Patients with severe renal(Creatinine more 1.5 times than upper limit of normal), gastrointestinal, hematological or hepatic(AST, ALT more 2 twice more than upper limit of normal)disease etc. which might affect absorption, disposition, metabolism or excretion of the drug~* Patients with postural hypotension~* Patients with sever insulin dependent diabetes mellitus or uncontrolled diabetes mellitus(HbA1c\>9%, regimen change of oral hypoglycemic agents within 3 months, treated insulin before screening)~* Patients with a history of myocardial infarction, severe coronary artery disease or clinically significant heart failure or valvular defect in last 6 months~* Patients with consumptive disease, autoimmune disease, connective tissue disease~* Patients with a history of type B or C hepatitis~* Patients with HIV or hepatitis~* Patients with clinically significant laboratory abnormality~* Patients receiving any drugs known to affect blood pressure or medical treatments that can influence the blood pressure~* Patients with allergy or contraindication to any angiotensin II receptor antagonists~* Female of childbearing potential who does not undergo hysterectomy or is not post-menopausal~* Patients judged to have a history of alcohol or drug abuse by the investigator~* Patients with average weight \> +35% or \<-15% in Modified Metropolitan Life Insurance table~* Patients participated other clinical trial 3 months before Screening~* Patients judged to be inappropriate for this study by the investigator with other reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 3 tablets of placebo will be taken 30minutes after breakfast for 8 weeks
- Fimasartan 20mg (Type: ACTIVE_COMPARATOR): 2 tablets of placebo and 1 tablets of fimasartan 20mg will be taken 30minutes after breakfast for 8 weeks
- Fimasartan 60mg (Type: ACTIVE_COMPARATOR): 3 tablets of fimasartan 20mg will be taken 30minutes after breakfast for 8 weeks
- Fimasartan 120mg (Type: ACTIVE_COMPARATOR): 3 tablets of fimasartan 40mg will be taken 30minutes after breakfast
- Fimasartan 240mg (Type: ACTIVE_COMPARATOR): 3 tablets of fimasartan 80mg will be taken 30minutes after breakfast for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).